Pleased to announce FDA approval of YARTEMLEA® (narsoplimab-wuug). First and only approved lectin pathway inhibitor therapy indicated for TA-TMA.
More info: bit.ly/497VHeF
#YARTEMLEA #narsoplimab #ComplementInhibition #RareDisease #TMAtreatment #NowApproved #MASP2inhibitor #tma #hsct #omeros #FDA

Omeros Corporation - Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA The Investor Relations website contains information about Omeros Corporation's business for stockholders, potential investors, and financial analysts.

Omeros announces robust improvement in survival for #narsoplimab expanded access program in #TA-TMA over external control. More info: shorturl.at/NA9fy #complementinhibitor #omeros

Omeros Corporation - Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint The Investor Relations website contains information about Omeros Corporation's business for stockholders, potential investors, and financial analysts.

Omeros announces newly completed sensitivity analyses demonstrating robustness of previously announced survival superiority over external control in #TA-#TMA More info: investor.omeros.com/news-release... #narsoplimab #complementinhibitor #omeros